ResMed Q1 FY27 diluted EPS rises 23% year-over-year to $2.92
RMD•ResMed’s Q1 FY27 GAAP diluted EPS rose 23% year over year to $2.92, while revenue increased 6% to $1.41 billion. Operating cash flow fell 8% to $422 million, and repurchases and dividends exceeded $1 billion.
1. Quarterly results
ResMed reported Q1 FY27 GAAP diluted EPS of $2.92, up 23% year over year, and revenue of $1.41 billion, up 6%, driven primarily by demand for sleep devices, masks and accessories. Operating cash flow declined 8% to $422 million, while shareholder returns through repurchases and dividends exceeded $1 billion. The MatrixCare divestiture closed, and the AirTouch F40 fabric CPAP mask launched in the U.S.
